The Safety and Effectiveness of Didanosine Plus Stavudine Plus Nevirapine Combined With MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors

This study has been terminated.
Sponsor:
Collaborators:
Boehringer Ingelheim
Triangle Pharmaceuticals
Information provided by:
Bristol-Myers Squibb
ClinicalTrials.gov Identifier:
NCT00002418
First received: November 2, 1999
Last updated: August 13, 2008
Last verified: March 2000
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: No date given